These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 12557133)

  • 1. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
    Laine L; Bombardier C; Hawkey CJ; Davis B; Shapiro D; Brett C; Reicin A
    Gastroenterology; 2002 Oct; 123(4):1006-12. PubMed ID: 12360461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.